SI1760088T1 - S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II - Google Patents

S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II

Info

Publication number: SI1760088T1
Authority: SI; Slovenia
Prior art keywords: molecules; tumour; present; relates; hla
Prior art date: 2005-09-05

Application number

SI200530167T

Other languages

English (en)

Inventor

Jorn Dengjel

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-05

Filing date

2005-09-05

Publication date

2008-06-30

2005-09-05 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2008-06-30 Publication of SI1760088T1 publication Critical patent/SI1760088T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI200530167T 2005-09-05 2005-09-05 S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II SI1760088T1 (sl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05019254A EP1760088B1 (en)	2005-09-05	2005-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Publications (1)

Publication Number	Publication Date
SI1760088T1 true SI1760088T1 (sl)	2008-06-30

Family

ID=35170099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
SI200531005T SI1806358T1 (sl)	2005-09-05	2005-09-05	S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
SI200530167T SI1760088T1 (sl)	2005-09-05	2005-09-05	S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II
SI200530994T SI1806359T1 (sl)	2005-09-05	2005-09-05	S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II
SI200631206T SI2135878T1 (sl)	2005-09-05	2006-09-05	S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule človeškega levkocitnega antigena HLA Human Leukocyte Antigen razreda II
SI200630566T SI1922335T1 (sl)	2005-09-05	2006-09-05	S tumorjem povezan peptid, ki se vedno veĹľe na molekule humanega levkocitnega antigena (HLA) razreda II

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI200531005T SI1806358T1 (sl)	2005-09-05	2005-09-05	S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
SI200530994T SI1806359T1 (sl)	2005-09-05	2005-09-05	S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II
SI200631206T SI2135878T1 (sl)	2005-09-05	2006-09-05	S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule človeškega levkocitnega antigena HLA Human Leukocyte Antigen razreda II
SI200630566T SI1922335T1 (sl)	2005-09-05	2006-09-05	S tumorjem povezan peptid, ki se vedno veĹľe na molekule humanega levkocitnega antigena (HLA) razreda II

Country Status (23)

Country	Link
US (6)	US10196432B2 (sl)
EP (6)	EP1806359B1 (sl)
JP (1)	JP5627180B2 (sl)
KR (3)	KR101386827B1 (sl)
CN (3)	CN105440119A (sl)
AT (5)	ATE461215T1 (sl)
AU (2)	AU2006289290B2 (sl)
BR (1)	BRPI0615462A2 (sl)
CA (2)	CA2929252A1 (sl)
CY (5)	CY1107973T1 (sl)
DE (4)	DE602005020047D1 (sl)
DK (5)	DK1806358T3 (sl)
EA (1)	EA013876B1 (sl)
ES (5)	ES2341802T3 (sl)
HK (1)	HK1220709A1 (sl)
HR (2)	HRP20100128T1 (sl)
NO (1)	NO340870B1 (sl)
NZ (2)	NZ566104A (sl)
PL (5)	PL1760088T3 (sl)
PT (5)	PT1806358E (sl)
SI (5)	SI1806358T1 (sl)
UA (1)	UA98295C2 (sl)
WO (1)	WO2007028574A2 (sl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE461215T1 (de) *	2005-09-05	2010-04-15	Immatics Biotechnologies Gmbh	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20090004213A1 (en)	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
SI2660248T1 (sl)	2007-07-27	2015-10-30	Immatics Biotechnologies Gmbh	Nova imunoterapija proti možganskim tumorjem
CN103360466B (zh)	2007-07-27	2016-08-03	伊玛提克斯生物技术有限公司	抗肿瘤相关肽及相关抗癌疫苗组合物
WO2009015842A2 (en)	2007-07-27	2009-02-05	Immatics Biotechnologies Gmbh	Novel immunogenic epitopes for immunotherapy
AU2008290060B2 (en) *	2007-08-20	2014-04-24	Oncotherapy Science, Inc.	CDH3 peptide and medicinal agent comprising the same
EP2215111B1 (en) *	2007-11-01	2016-03-16	Mayo Foundation For Medical Education And Research	Hla-dr binding peptides and their uses
DK2105501T3 (da)	2008-03-27	2015-11-23	Immatics Biotechnologies Gmbh	Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer
DK2113253T3 (da)	2008-04-30	2010-07-19	Immatics Biotechnologies Gmbh	Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
PT2119726E (pt)	2008-05-14	2015-03-30	Immatics Biotechnologies Gmbh	Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
EP2172211B1 (en) *	2008-10-01	2014-12-03	Immatics Biotechnologies GmbH	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2010085879A1 (en) *	2009-01-28	2010-08-05	Industrial Technology Research Institute	Urine and serum biomarkers associated with diabetic nephropathy
US9023802B2 (en)	2009-12-14	2015-05-05	Immatics Biotechnologies Gmbh	HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en)	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
NZ609916A (en)	2010-12-14	2015-03-27	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
SG193591A1 (en) *	2011-03-23	2013-10-30	Hutchinson Fred Cancer Res	Method and compositions for cellular immunotherapy
HUE057334T2 (hu)	2013-08-05	2022-05-28	Immatics Biotechnologies Gmbh	Új immunterápia többféle tumor, például tüdõrák ellen, az NSCLC-t is beleértve
TWI777197B (zh) *	2013-08-05	2022-09-11	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六）
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en)	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (hr)	2014-05-09	2019-12-13	Immatics Biotechnologies Gmbh	Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
MD3626731T2 (ro)	2014-12-23	2022-01-31	Immatics Biotechnologies Gmbh	Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și a altor cancere
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
LT3388075T (lt)	2015-03-27	2023-11-10	Immatics Biotechnologies Gmbh	Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
EA201792531A1 (ru) *	2015-06-19	2018-05-31	Имматикс Байотекнолоджиз Гмбх	Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака
MA54884A (fr)	2015-07-01	2022-01-12	Immatics Biotechnologies Gmbh	Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN113880938B (zh)	2015-07-06	2025-09-05	伊玛提克斯生物技术有限公司	用于食管癌和其他癌症免疫治疗的新型肽和肽组合物
MY189596A (en)	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI782433B (zh)	2015-08-28	2022-11-01	德商英麥提克生物技術股份有限公司	用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
PH12022551111A1 (en)	2015-10-05	2023-08-23	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY196837A (en)	2015-12-11	2023-05-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
CA3008641A1 (en)	2015-12-16	2017-06-22	Gritstone Oncology, Inc.	Neoantigen identification, manufacture, and use
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
IL302705A (en)	2016-03-01	2023-07-01	Immatics Biotechnologies Gmbh	Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) *	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
LT3436048T (lt) *	2016-03-31	2026-01-12	Biontech Us Inc.	Neoantigenai ir jų naudojimo būdai
JP6989136B2 (ja)	2016-04-06	2022-01-05	イマティクスバイオテクノロジーズゲーエムベーハー	Ａｍｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
SG10202006117QA (en)	2016-04-21	2020-08-28	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
EA201892333A1 (ru)	2016-04-21	2019-03-29	Имматикс Байотекнолоджиз Гмбх	Иммунотерапия меланомы и других видов рака
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
CN109997041B (zh) *	2016-06-10	2022-10-28	歌德塔有限公司	人白细胞抗原限制的γδT细胞受体及其使用方法
TW202304970A (zh)	2016-08-26	2023-02-01	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
NZ754222A (en)	2016-12-08	2022-02-25	Immatics Biotechnologies Gmbh	T cell receptors with improved pairing
MA47367B1 (fr)	2017-01-27	2023-06-28	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
BR112019015237A2 (pt)	2017-01-27	2020-04-14	Immatics Biotechnologies Gmbh	peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de ovário e outros cânceres
AR110857A1 (es)	2017-01-27	2019-05-08	Immatics Biotechnologies Gmbh	Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
EP3576767A4 (en) *	2017-02-06	2020-12-02	Academia Sinica	RECOMBINATED PROTEINS AND THEIR USES
TW201841934A (zh)	2017-04-10	2018-12-01	德商英麥提克生物技術股份有限公司	用於治療癌症免疫治療的新穎肽及其肽組合物
PE20191617A1 (es)	2017-04-10	2019-11-05	Immatics Biotechnologies Gmbh	Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer
CN111533797A (zh) *	2017-04-10	2020-08-14	伊玛提克斯生物技术有限公司	用于癌症免疫治疗的肽及其肽组合物
EA201992416A1 (ru)	2017-04-10	2020-02-25	Имматикс Байотекнолоджиз Гмбх	Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
EP4316597A3 (en)	2017-07-07	2024-11-06	immatics biotechnologies GmbH	Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
WO2019007974A1 (en)	2017-07-07	2019-01-10	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
EP3684196B1 (en)	2017-09-18	2024-09-04	S & P Ingredient Development, LLC	Low sodium salt substitute with potassium chloride
EP3694532B1 (en)	2017-10-10	2025-02-26	Gritstone bio, Inc.	Neoantigen identification using hotspots
WO2019104203A1 (en)	2017-11-22	2019-05-31	Gritstone Oncology, Inc.	Reducing junction epitope presentation for neoantigens
DE102018108996B4 (de)	2018-02-09	2021-10-21	Immatics US, Inc.	Verfahren zur Herstellung autologer T-Zellen
EP3749753B1 (en)	2018-02-09	2025-04-02	Immatics US, Inc.	Methods for manufacturing t cells
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2019168984A1 (en) *	2018-02-27	2019-09-06	Gritstone Oncology, Inc.	Neoantigen identification with pan-allele models
EP3539562A1 (en) *	2018-03-12	2019-09-18	Eberhard Karls Universität Tübingen Medizinische Fakultät	Immunotherapeutic peptides
TW202016131A (zh)	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
US10925947B2 (en)	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh)	2018-07-31	2020-06-01	德商英麥提克生物技術股份有限公司	B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh)	2018-09-17	2020-08-01	德商英麥提克生物技術股份有限公司	B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh)	2018-09-18	2020-07-01	德商英麥提克生物技術股份有限公司	A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh)	2018-12-18	2020-11-01	德商英麥提克生物技術股份有限公司	B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) *	2019-03-28	2021-02-15	한국과학기술연구원	인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
ES2991645T3 (es)	2019-06-06	2024-12-04	Immatics Biotechnologies Gmbh	Clasificación con contraselección mediante péptidos de secuencia similar
CN110305209B (zh) *	2019-07-09	2022-09-13	福建医科大学附属第一医院	用于治疗恶性肿瘤的多肽及其作为疫苗的用途
AU2020320445A1 (en) *	2019-07-30	2022-03-03	University Health Network	T cell receptors and methods of use thereof
EP3827840A1 (en) *	2019-11-29	2021-06-02	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	Teipp peptide variant and uses thereof
US11891427B2 (en)	2020-09-29	2024-02-06	Immatics Biotechnologies Gmbh	Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
DE102020125465A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh)	2021-01-15	2022-11-01	德商英麥提克生物技術股份有限公司	用於不同類型癌症免疫治療的ｈｌａ展示肽
CN120712104A (zh) *	2022-10-14	2025-09-26	广东天科雅生物医药科技有限公司	针对神经胶质瘤的肽疫苗及其用途
CN117720620B (zh) *	2023-12-13	2024-07-23	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8258260B2 (en) *	1970-02-11	2012-09-04	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (sl) *	1977-09-20	1981-01-14	Licinvest Ag
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
IL59007A (en)	1978-12-22	1983-11-30	Biogen Nv	Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en) *	1987-01-15	1989-03-07	The George Washington University	Methods of preparing epitopes of tumor associated antigens
FI944575L (fi) *	1992-04-03	1994-11-29	Jolla Cancer Res Found	Dekoriinigragmentteja ja menetelmiä solunsäätelytekijöiden inhiboimiseksi
EP0671926B1 (en) *	1992-08-11	2002-11-13	President And Fellows Of Harvard College	Immunomodulatory peptides
EP0725799A1 (en) *	1993-10-29	1996-08-14	Dana-Farber Cancer Institute, Inc.	A novel tumor marker and novel method of isolating same
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
JPH10506004A (ja)	1994-07-27	1998-06-16	ザカウンシルオブザクィーンズランドインスティテュートオブメディカルリサーチ	ポリエピトープワクチン
UY24367A1 (es) *	1995-11-23	2000-10-31	Boehringer Ingelheim Int	Vacunas contra tumores y procedimiento para su produccion
ATE244300T1 (de)	1996-01-17	2003-07-15	Imp College Innovations Ltd	Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US6610821B1 (en) *	1996-07-12	2003-08-26	Mcgill University	Compounds and methods for modulating endothelial cell adhesion
US6046031A (en) *	1997-01-21	2000-04-04	Human Genome Sciences, Inc.	Metalloproteinases
US6316213B1 (en)	1997-03-19	2001-11-13	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian, breast and lung cancer
EP1023445B1 (de) *	1997-10-15	2005-08-17	Pharis Biotec GmbH	Cadherin derived growth factor und seine verwendung
DE19757250A1 (de) *	1997-12-22	1999-07-01	Forssmann Wolf Georg Prof Dr	Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) *	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de)	1999-08-04	2001-02-08	Boehringer Ingelheim Int	Tumorassoziiertes Antigen
DE19938583A1 (de)	1999-08-18	2001-02-22	Buehler Ag	Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
AU2001236589A1 (en) *	2000-02-04	2001-08-14	Aeomica, Inc.	Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
AU2001278070A1 (en) *	2000-07-26	2002-02-05	Applied Genomics, Inc.	Basal cell markers in breast cancer and uses thereof
AU2001295582A1 (en)	2000-12-20	2002-07-01	GlaxoSmithKline Biologicals (s.a.)	Tumour-related antigens
WO2002078516A2 (en) *	2001-03-30	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
WO2003004989A2 (en) *	2001-06-21	2003-01-16	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE403149T1 (de) *	2001-08-13	2008-08-15	Dana Farber Cancer Inst Inc	Diagnostische tests auf periostinbasis
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
WO2003030836A2 (en) *	2001-10-12	2003-04-17	Case Western Reserve University	Neuronal regeneration
US20050100554A1 (en) *	2002-02-14	2005-05-12	Amanda Jackson	Complexes and methods of using same
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
AU2002368151A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US20070224201A1 (en) *	2002-10-02	2007-09-27	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP1560597A4 (en) *	2002-10-29	2007-06-27	Pharmacia Corp	DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
JP2007504842A (ja) *	2003-05-29	2007-03-08	ミレニアムファーマシューティカルズ，インコーポレイテッド	乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
EP1646648A2 (en) *	2003-07-15	2006-04-19	Genova Ltd.	Secreted polypeptide species reduced in cardiovascular disorders
EP1757940A1 (en)	2005-08-26	2007-02-28	Cézanne S.A.S.	In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
ATE461215T1 (de) *	2005-09-05	2010-04-15	Immatics Biotechnologies Gmbh	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
DK1760089T3 (da) *	2005-09-05	2009-11-16	Immatics Biotechnologies Gmbh	Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
EP1795599A1 (en) *	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Methods for generating antigen-specific effector T cells

2005
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Expired - Lifetime
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es not_active Expired - Lifetime
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es not_active Expired - Lifetime
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de not_active Expired - Lifetime
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de not_active Expired - Lifetime
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Expired - Lifetime
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Expired - Lifetime
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es not_active Expired - Lifetime
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de not_active Expired - Lifetime
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
2006
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active Expired - Fee Related
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active Expired - Fee Related
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en not_active Ceased
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active Expired - Fee Related
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
2007
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown

Also Published As

Publication number	Publication date
EP2135878B1 (en)	2011-11-09
CY1112186T1 (el)	2015-12-09
NO340870B1 (no)	2017-07-03
EP1922335A2 (en)	2008-05-21
KR101386827B1 (ko)	2014-04-17
ATE532795T1 (de)	2011-11-15
AU2006289290B2 (en)	2010-11-25
PT2135878E (pt)	2012-01-05
CA2621389C (en)	2016-07-19
US7833970B2 (en)	2010-11-16
ES2337399T3 (es)	2010-04-23
CY1107973T1 (el)	2013-09-04
EA013876B1 (ru)	2010-08-30
PL1922335T3 (pl)	2010-05-31
US20080206218A1 (en)	2008-08-28
US20100040590A1 (en)	2010-02-18
US20080206216A1 (en)	2008-08-28
DE602005020046D1 (de)	2010-04-29
KR20130019034A (ko)	2013-02-25
ATE388164T1 (de)	2008-03-15
AU2006289290A1 (en)	2007-03-15
BRPI0615462A2 (pt)	2011-05-17
CN105440119A (zh)	2016-03-30
ES2302546T3 (es)	2008-07-16
NZ588813A (en)	2011-06-30
EP1806359A1 (en)	2007-07-11
AU2010236029A1 (en)	2010-11-18
KR101386790B1 (ko)	2014-04-21
PT1922335E (pt)	2010-03-03
DK1806358T3 (da)	2010-06-28
EP2138509A1 (en)	2009-12-30
CA2929252A1 (en)	2007-03-15
EP2135878A1 (en)	2009-12-23
SI1806359T1 (sl)	2010-06-30
HRP20110981T1 (hr)	2012-02-29
US10196432B2 (en)	2019-02-05
DK2135878T3 (da)	2012-02-27
SI1806358T1 (sl)	2010-06-30
KR20130019033A (ko)	2013-02-25
ATE461214T1 (de)	2010-04-15
ES2341295T3 (es)	2010-06-17
HK1183678A1 (en)	2014-01-03
NZ566104A (en)	2011-04-29
DE602005005196T2 (de)	2008-06-26
HK1220709A1 (zh)	2017-05-12
DE602006011030D1 (de)	2010-01-21
ES2341802T3 (es)	2010-06-28
PL1760088T3 (pl)	2008-10-31
PL1806359T3 (pl)	2010-08-31
CN103059104B (zh)	2015-10-28
US20080207520A1 (en)	2008-08-28
DK1760088T3 (da)	2008-06-09
US10618945B2 (en)	2020-04-14
EP1806358A2 (en)	2007-07-11
EP1806358A3 (en)	2007-10-03
EP1760088A1 (en)	2007-03-07
ATE461215T1 (de)	2010-04-15
DK1806359T3 (da)	2010-06-14
CY1110051T1 (el)	2015-01-14
DE602005020047D1 (de)	2010-04-29
US7833969B2 (en)	2010-11-16
JP5627180B2 (ja)	2014-11-19
WO2007028574A2 (en)	2007-03-15
US7807642B2 (en)	2010-10-05
PL2135878T3 (pl)	2012-06-29
PL1806358T3 (pl)	2010-08-31
UA98295C2 (ru)	2012-05-10
ES2373907T3 (es)	2012-02-10
HRP20100128T1 (hr)	2010-04-30
WO2007028574A3 (en)	2007-05-24
KR101386355B1 (ko)	2014-04-17
EP1806358B1 (en)	2010-03-17
EP1922335B1 (en)	2009-12-09
CN101287754A (zh)	2008-10-15
CN101287754B (zh)	2013-02-13
EP1806359B1 (en)	2010-03-17
EP1760088B1 (en)	2008-03-05
PT1806358E (pt)	2010-05-28
JP2010502173A (ja)	2010-01-28
SI1922335T1 (sl)	2010-04-30
WO2007028574A9 (en)	2008-05-02
PT1806359E (pt)	2010-05-25
US20160115212A1 (en)	2016-04-28
DK1922335T3 (da)	2010-04-19
PT1760088E (pt)	2008-05-14
NO20081683L (no)	2008-04-04
CY1109849T1 (el)	2014-09-10
US20080206217A1 (en)	2008-08-28
KR20080052643A (ko)	2008-06-11
SI2135878T1 (sl)	2012-03-30
CY1110187T1 (el)	2015-01-14
CN103059104A (zh)	2013-04-24
AU2010236029B2 (en)	2012-06-28
EA200800677A1 (ru)	2008-08-29
DE602005005196D1 (de)	2008-04-17
ATE451388T1 (de)	2009-12-15
CA2621389A1 (en)	2007-03-15

Publication	Publication Date	Title
PL1760088T3 (pl)	2008-10-31	Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
PL1760089T3 (pl)	2010-03-31	Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
PL1642905T3 (pl)	2009-04-30	Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy